Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BKT140 + Nelarabine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BKT140 | TN14003|BL-8040|BL8040|Motixafortide | CXCR4 Inhibitor 15 | BL-8040 (BKT140) is a selective CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may lead to decreased tumor growth (PMID: 21138752). | |
| Nelarabine | Arranon | GW-506U78 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02763384 | Phase II | BKT140 + Nelarabine | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | Terminated | USA | 0 |